Virtus ETF Advisers’s Caribou Biosciences CRBU Stock Holding History

Virtus ETF Advisers’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,044	Closed	-$72.2K	–	458
2024 Q1	$72.2K	Sell	14,044 -961	-6%	-$5.93K	0.04%	407
2023 Q4	$86K	Sell	15,005 -6,353	-30%	-$31.4K	0.05%	413
2023 Q3	$102K	Sell	21,358 -2,128	-9%	-$13.2K	0.06%	331
2023 Q2	$99.8K	Buy	23,486 +11,087	+89%	+$49.8K	0.06%	381
2023 Q1	$65.8K	Sell	12,399 -4,766	-28%	-$29.7K	0.04%	410
2022 Q4	$108K	Sell	17,165 -3,204	-16%	-$28.5K	0.06%	436
2022 Q3	$215K	Buy	20,369 +154	+0.8%	+$1.44K	0.09%	312
2022 Q2	$110K	Buy	20,215 +10,823	+115%	+$82.7K	0.04%	408
2022 Q1	$86K	Sell	9,392 -557	-6%	-$5.87K	0.04%	326
2021 Q4	$150K	Buy	+9,949	New	+$193K	0.06%	347

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's CRBU Position: Q2 2024 in Review

Virtus ETF Advisers sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 14,044 shares — an estimated $72.2K sold.

Virtus ETF Advisers first reported a position in CRBU in Q4 2021 and held it in 10 quarters. The position peaked at $215K in Q3 2022. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

Virtus ETF Advisers reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
Virtus ETF Advisers sold 14,044 Caribou Biosciences shares in Q2 2024, an estimated $72.2K.
Virtus ETF Advisers first reported a position in Caribou Biosciences in Q4 2021 and held it in 10 quarters.
Virtus ETF Advisers's Caribou Biosciences position peaked at $215K in Q3 2022.
140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.